Alpha Tau 100% Local Disease Control, Favorable Safety in Pancreatic Cancer Trials

 - 100% local disease control rate achieved in evaluable patients in pooled analysis of two first-in-human trials of Alpha DaRT^® in pancreatic adenocarcinoma -

- Favorable safety profile observed, with only 8 device-associated adverse events in 7 of 26 subjects (27%), nearly all resolving within two weeks in some of the most challenging, heavily pre-treated patients in oncology -

- Highly heterogeneous patient population for whom available options are extremely limited included patients ineligible for chemotherapy as well as patients who had received up to four prior lines of chemotherapy -

- Streamlined outpatient endoscopic ultrasound (EUS)-guided procedure designed for seamless integration into standard GI endoscopy workflow -

- Results shared in oral presentation at DDW 2026, the first presentation of Alpha DaRT at a premier international gastroenterology conference -

https://www.biospace.com/press-releases/alpha-tau-announces-100-local-disease-control-rate-and-favorable-safety-profile-observed-in-alpha-dart-pancreatic-cancer-trials-presented-at-ddw-2026